Presenting features and treatment outcomes of chronic lymphocytic leukaemia in a resource poor Southern Nigeria

• Published in: Malawi medical journal 2019-06, Vol.31 (2), p.144-149
• Main Authors: Madu, Anazoeze Jude, Korubo, Kaladada, Okoye, Augustine, Ajuba, Ifeoma, Duru, Augustine N, Ugwu, Angela O, Nnachi, Oji, Okoye, Helen Chioma
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase - blood; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Aspartate Aminotransferases - blood; Chlorambucil - therapeutic use; Female; Hematology; Humans; Laboratories; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell - blood; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell - mortality; Male; Males; Middle Aged; Nigeria - epidemiology; Original Research; Patients; Phosphatase; Retrospective Studies; Survival Rate; Treatment Outcome
• ISSN: 1995-7262; 1995-7270; 1995-7262
• DOI: 10.4314/mmj.v31i2.7

Chronic lymphocytic leukaemia is a relatively common haematological malignancy affecting older adults, accounting for about 20% of haematological malignancies in Nigeria. Diagnosis of this disease depends on the demonstration of clonal lymphocytosis > 5 × 109/L with a characteristic immunophenotypic pattern amidst other clinical and laboratory features. To determine the predominant clinical and laboratory features of CLL at presentation and their relationship with patient survival. This study also aims at examining the relationship between treatment protocol and outcome. This is a retrospective study with 8 years data (2010-2018) collected from four different centers. Data was analyzed using SPSS 20.0. There were a total of 97 cases, with a male: female ratio of 1.1:1. The median age at presentation was 59 years. Approximately 55% of the patients presented at Binet stage C, with splenomegaly in 93.2% and 78% were anaemic. The mean white cell count was 137.9 ± 14.7 × 109/L, with a median absolute lymphocyte count of 86 × 109/L. The commonest treatment regimen was chlorambucil and prednisolone and males had a superior response. The number of chemotherapy cycles, serum alkaline phosphatase and aspartate transaminase correlated positively with duration of survival. Mortality rate over the five year period was 14.3%. CLL was found to present in younger patients when compared to previous studies with a median age of 57 years at diagnosis. Our study showed a slight female preponderance and better response to therapy in males. Majority of the patients presented in Binet stage C and were treated with chlorambucil-based drug combinations compared to more current treatment with Fludarabine-based combinations. A high serum alanine transaminase and alkaline phosphatase was found to positively correlate with survival amongst this patient population.